Eight med spa systems, 929+ clinics, 42 public sources: how the consolidated head of a cash-pay category buys demand, measures it, and where the measurement breaks before the revenue.
Cash-pay means the patient pays out of pocket, with no insurer in the transaction, and that one fact shapes the whole market. A dermatology practice gets patients from physician referrals and insurer directories; a med spa has no such pipeline, so it competes for consumers the way retail does.
Cash-pay also often means outside HIPAA, because covered-entity status turns on electronic insurance billing. That does not make tracking safe: state laws like Washington's My Health My Data Act and the CCPA enforcement wave fill the gap.
For ad, media and digital agencies
Built for the working moments of this category: qualifying a med spa account before the pitch deck exists, preparing or defending a deck with sourced numbers, answering "what is a good CPL here" in a benchmark conversation, and reading a franchise prospect's disclosure terms to see who owns the advertising obligation and its data.
For marketing teams inside multi-location operators
The four-stage maturity model works as a self-assessment against the operator's own stack, and the three plays written for each stage read as the next quarter's roadmap.
For operators and investors heading into a transaction
The consolidation record carries both outcomes: systems whose measurement survived diligence, and the category's former number three that collapsed. The thesis names the cost, measurement debt comes due at exit.
The measurement problem
Borrowed benchmarks, borrowed signal, and borrowed claims all break before the revenue.
The only solution is to own the join yourself: the ad, the booking, the attended treatment, and the revenue it created, connected end to end. Every section below shows one place that join breaks and what it costs to leave it broken. Own the join, or pay the measurement debt at exit.
Market read
The gap is not activity. It is knowing which combination pays.
National creative and offer systems meet local inventory, practitioner schedules, financing, and franchise economics. What creates attended, profitable treatment and repeat revenue differs by market. Four lenses translate the public evidence into the questions a category marketer needs to answer: how demand is created, where conversion happens, where measurement breaks, and what to change.
Creative and offers manufacture demand
Paid social, financing, promotions, and treatment education can move a discretionary consumer before local intent exists.
The booked consultation must become treatment
Lead volume hides the operational step from consultation to attended, financed, and completed procedure.
National creative meets local inventory
A winning message can look weak where practitioner schedules, treatment availability, or follow-up speed constrain conversion.
Read creative by market economics
Join concept, offer, audience, location, appointment capacity, show rate, and treatment revenue before scaling spend.
Benchmark reality
No defensible public med-spa CPL or CAC benchmark exists
The largest public healthcare ad-benchmark set has no med-spa category: LocaliQ's January 2026 edition covers 3,542 US healthcare search campaigns run between October 2024 and September 2025, sorted into 16 categories, none of them med spa. The two nearest to injectable and laser work, Plastic & Cosmetic Surgery and Dermatology, report costs per lead 5.5x apart. Picking either one is picking an answer. Everything med-spa-specific in circulation is either operational data or one vendor's own client sample.
The sharpest example sits inside this page's own source list. The AmSpa blog article behind the $2,500 figure also publishes a $39 cost per lead, a $132 new-patient acquisition cost, and a 5%-of-revenue recommendation. A software vendor wrote it, it names no sample, no date range and no method, and the same vendor attributes a 7% observed average to a different study elsewhere on the same blog . A recommendation and an observed average sitting side by side under one byline are not a benchmark. A client can find these in one search, so name them first and say why they do not survive.
That is the reality an analyst defends numbers inside. The inventory below carries its evidence tier at point of use: the honest move in a client deck is to cite the tier, not to launder a directional number into a market fact.
The visible asymmetry is on Google, and it is almost all Maps
As captured on July 26, 2026, Milan Laser had ~9,000 active Google ads, ~8,000 of them Maps placements, and ~190 active Meta ads; LaserAway had ~320 active Meta ads while its verified Google advertiser page showed an age-gated floor of 14 ads to a signed-out viewer.
On Meta the two run close, ~190 against ~320. The asymmetry is on Google, where LaserAway's signed-out page shows a floor set by age-gating rather than a true count.
Same category, same offer grammar, and one of them puts nearly all its visible search demand into Maps.
Later captures moved: on August 5 Milan's Google reading held at ~9,000 and LaserAway's signed-out floor read 15, and on August 8 LaserAway's Meta count read ~270. These are dated snapshots of activity, not a running count, so read every pair on its own date.
tier a Ad transparency library captures, 2026-07-26
Methodology and denominator
Denominator: the two largest systems by verified footprint within the tracked eight-system cohort, itself the consolidated head of a market AmSpa reports as 81% single-location. Observable: active ad-library creatives in the Google Ads Transparency Center and Meta Ad Library on the capture date. Activity, never spend. The former third-largest system, Ideal Image, collapsed in late 2025 and is excluded from the active cohort; survivorship is disclosed, not hidden. Advertiser IDs for independent re-capture: Milan Laser AR03532472337372807169, LaserAway AR03751231617511718913.
What public evidence actually offers, tier by tier
| Metric | Best public figure | Source | Tier | Caveat |
|---|---|---|---|---|
| Search CPL, nearest available proxies | Plastic surgery $102.51 · Dermatology $18.54 | LocaliQ healthcare search benchmarks (n=3,542 US campaigns run 2024-10-01 to 2025-09-30; published 2026-01-13) ↗ | tier c | Neither category is med spa, and the two closest candidates disagree by 5.5x. Search only. Reported cost per lead does not reconcile to the same table's cost per click and conversion rate, so the three are not one funnel. |
| Med-spa-specific paid CPL | Meta $30-80 · Google $40-120 · Botox: Meta $25-55, Google $45-90 | Pennock agency benchmarks from its own client campaigns (2026-04-07) ↗ | tier c | One agency's self-reported client data; no sample size disclosed. Directional only. |
| Total marketing as share of revenue | 7% average, 2-15% range | Growth99's CEO writing on AmSpa's blog (2025-05-02), citing AmSpa's 2024 State of the Industry Report ↗ | tier c | Total marketing, not paid media. Vendor-authored, and AmSpa's own public recap of that report does not carry the figure, so the underlying sample cannot be checked. |
| Operational and revenue benchmarks | Location growth, membership mix, revenue per location | Zenoti 2025 medspa benchmark edition (platform data; 30,000+ businesses served) ↗ | tier c | Transaction-platform sample; operations, not media efficiency. |
| Consumer booking behavior | Survey of 2,000+ self-care consumers | Boulevard Self-Care Client Report 2026 ↗ | tier c | Consumer preference data; report gated. |
| Aesthetics marketing-practice survey | Practitioner survey; figures inside gated report | Growth99 2026 State of Aesthetic & Elective Wellness Marketing ↗ | tier c | The only marketing-specific aesthetics survey line; sample size undisclosed on the public page. |
| Category ad activity | ~9,000 Google at one system, ~8,000 of them Maps | Google Ads Transparency Center + Meta Ad Library captures, 2026-07-26 | tier a | Dated activity observation; not spend, not efficiency. Meta counts run close between the two largest systems (~190 and ~320); the Google gap is partly age-gating, not absence. |
Keep the denominator attached to every number
The strongest public evidence spans total marketing, local advertising, and brand funds. Those are different measures. This ladder shows what each figure can support, and where it stops.
Category-wide Google + Meta budget or CPL
No primary public source with a stated med-spa denominator supports a universal channel budget, CPL, consultation rate, show rate, or treatment CAC.
Calculate these from the operator's own media, scheduler, treatment, and revenue data. AmSpa study recap ↗AmSpa 2024 study signal
The public recap reports total marketing relative to practice revenue across participating practices but does not disclose the exact respondent count.
Useful as directional category context only; do not republish the percentage as an adoption or paid-media benchmark. AmSpa 2024 study recap ↗Franchise local-marketing obligation
VIO's Minnesota-registered disclosure dated March 13, 2026 requires 6% of monthly gross sales on pre-approved local marketing through month 24, then 4% while the location meets its minimum sales requirements, 2.5% above $3M in annual gross sales, and 1.5% above $4M. Royalty and the brand development fund are separate line items. The filing is operator-specific, not a med-spa denominator.
Model local obligation, brand fund, and royalty as separate fields, and record which rung each location sits on before comparing franchise locations. VIO FDD, Minnesota registration, 2026-03-13 ↗Maturity model
Four maturity stages, each with a test an account passes or fails
Each stage has a yes/no test a client account either passes or fails, which turns portfolio review into an audit an agency can run across every healthcare client in an afternoon. What carries the stage label is one account's measurement setup, not the agency that built it, and the labels make no claim about how the market distributes across stages.
The measurement maturity model
- Stage 1
Platform defaults
Reporting lives inside each ad platform's own dashboard. Conversions are platform-defined, calls are invisible, and any location-level number requires manual export.
The testDoes every performance number the client sees originate inside an ad platform's own dashboard?
- Stage 2
Owned tracking baseline
The client account owns its analytics: site-side tracking with consent management live on every domain, booking conversions recorded as first-party events, and offline outcomes imported on a regular cadence.
The testCan you show last month's booked consultations per location from the client's own analytics property?
- Stage 3
Location-grade attribution
Cost and booked appointments reconcile per location per channel, calls carry campaign attribution, and booking-system outcomes join back to media without hand-built spreadsheets.
The testCan the client report cost and booked appointments per location per channel, including calls, without hand-built spreadsheets?
- Stage 4
Warehouse-owned measurement
Location-level marketing and booking data lands in a client-controlled warehouse on a schedule, identity and consent boundaries are documented, and reporting survives platform signal changes because the client owns the join.
The testDoes location-level marketing plus booking data land in a client-controlled warehouse on a schedule, with documented consent and PHI boundaries?
The category sells a low-risk first step. Measurement has to survive seven.
A consultation is commercially useful only when it can be joined to attendance, treatment mix, collected revenue, and repeat care. Clinic and provider capacity belong in that join because a market cannot convert demand it cannot schedule.
- 01 Demand
Paid search, paid social, creators, local discovery
- 02 Offer
Consultation, analysis, package, or financing promise
- 03 Lead
Form, call, chat, or virtual consultation
- 04 Booked
Clinic, treatment interest, and appointment slot
- 05 Attended
The first operational outcome; no-show loss is visible
- 06 Treated
Service mix, discount, financing, and collected revenue
- 07 Retained
Repeat treatment, membership, loyalty, and referral
Low-risk first step
A free consultation or skin analysis turns a complex treatment choice into a conversation.
Personalized plan
The consultation reframes the sale around goals, treatment mix, and a staged plan rather than one procedure.
Affordability bridge
Packages, financing, and monthly framing reduce the upfront price barrier without proving unit economics.
Lifecycle layer
Memberships, loyalty, and recurring treatment convert acquisition into a longer relationship.
AI adoption
Nine workflows: what AI changes, and what it still cannot fix
Med Spa has visible AI adoption in booking, lead response, charting, and lifecycle automation, while profitable treatment attribution still depends on manual offer governance, local capacity, and joins across media, calls, scheduler, POS, financing, and clinical records.
Zenoti and Liine prove current med-spa capabilities and selected operator use cases. Platform claims do not establish adoption across the eight systems, so no category percentage is published.
Creative production
Emerging Maturity basis · Cross-industry proxyMeta and Google can generate or transform image, video, audio, and placement variants from approved assets.
Still manual / non-AITeams still source consented before/after material, validate treatment claims, choose offers, preserve brand, and approve local applicability.
Meta documents generative variation and optimization; it publishes no med-spa-specific adoption denominator.
Procedure claims, patient-image consent, sensitive targeting, and clinic-specific treatment inventory constrain unsupervised variation.
Message and copy generation
Emerging Maturity basis · Verified industry evidenceMed-spa platforms generate personalized follow-ups, rebooking, win-back, treatment quotes, and campaign messages from booking and visit context.
Still manual / non-AIClinical promises, contraindications, financing terms, local pricing, voice, and exception handling remain human-reviewed.
Zenoti documents AI-powered marketing automation, personalized quotes, and follow-up workflows purpose-built for med spas.
Treatment history can improve relevance but also increases privacy and governance risk when reused for marketing.
Paid-media optimization
Widespread Maturity basis · Cross-industry proxyGoogle Smart Bidding and Meta Advantage+ automate bids, audiences, placements, and creative selection.
Still manual / non-AIMarketers still define geo, treatment, offer, budget, margin guardrails, exclusions, and the conversion event sent back to each platform.
Liine publishes a healthcare operator testimonial about optimizing Google Ads to bookings rather than clicks or calls; it is an operator example, not a med-spa rate.
A lead or booking feedback loop ignores attendance, discount, provider time, treatment mix, financing, and repeat value.
SEO and GEO
Emerging Maturity basis · Improvado hypothesisAI marketing platforms can audit online presence, automate reputation workflows, and suggest local visibility actions.
Still manual / non-AILocation/service facts, provider credentials, medically reviewed content, local differentiation, and resolution of conflicting listings remain manual.
Zenoti describes online-presence auditing, campaign automation, segmentation, and revenue attribution for med spas and wellness businesses.
Aesthetics pages change offers and providers quickly, while AI answers need stable, structured, clinically accurate local facts.
UTM, attribution, and data QA
Rare Maturity basis · Improvado hypothesisAI-enabled healthcare attribution tools can classify calls, reconcile repeat touchpoints, and surface gaps across calls, forms, and bookings.
Still manual / non-AIOffer taxonomy, clinic IDs, scheduler mappings, revenue joins, financing, refunds, and offline conversion validation still require governed data work.
Liine documents session-level attribution across calls, forms, and 20+ scheduling platforms, including med-spa operator examples.
AI cannot infer reliable profitability when source, offer, appointment status, treatment, discount, and collected revenue never share a key.
Call analysis
Emerging Maturity basis · Operator exampleAI call tools transcribe, classify intent, score booking behavior, identify missed opportunities, and coach staff.
Still manual / non-AITeams still validate disposition, resolve clinical questions, coach nuanced conversations, and connect calls to attendance and treatment revenue.
Liine publishes Ageless and Pure Luxe examples tying call intelligence to additional consultations and less clinical-staff dependence.
A booked consultation can still no-show, convert to a low-margin service, or be constrained by provider capacity.
Lead routing and CRM
Emerging Maturity basis · Verified industry evidenceAI lead managers capture inquiries, respond across channels, qualify intent, automate follow-up, and expose pipeline analytics.
Still manual / non-AIClinical suitability, high-risk questions, financing exceptions, ownership conflicts, and stalled-lead escalation remain human workflows.
Zenoti documents multichannel capture, AI lead scoring, automated follow-ups, and pipeline analytics for med spas.
Fast response does not solve inaccurate service/location routing or disconnected clinical and financial qualification.
Scheduling and patient engagement
Emerging Maturity basis · Verified industry evidenceAI receptionists answer missed calls, continue by SMS, book or reschedule, fill waitlists, recover abandoned bookings, and trigger rebooking.
Still manual / non-AIComplex treatment sequences, contraindications, provider overrides, deposits, financing, and adverse-event escalation stay with staff.
The current med-spa platform documents AI booking, waitlist, missed-call recovery, and provider-capacity workflows.
Inventory includes rooms, devices, injectors, clinicians, treatment spacing, deposits, and local operating rules, not just open calendar slots.
Compliance and privacy
Rare Maturity basis · Improvado hypothesisAI can assist charting, redact transcripts, review content against policies, and flag risky data flows, but it does not determine the legal lane.
Still manual / non-AIEntity status, consent, BAAs, state law, treatment claims, before/after permissions, audience eligibility, and incident response remain accountable decisions.
Zenoti documents AI-assisted HIPAA-ready workflows; HHS separately defines regulated tracking disclosures. Capability is not a compliance finding.
The same med-spa brand can operate covered and non-covered surfaces, while ad platforms separately restrict sensitive-health targeting.
Operating model
Multi-location med spa is not one operating model
AmSpa's 2024 public recap says single-location practices dominate the wider market but does not state the exact respondent count. This research studies the exception: eight active systems and 929+ clinics where national demand, local capacity, booking, treatment revenue, and lifecycle data have to meet.
The enterprise cohort is the exception, not the category average
AmSpa's 2024 recap describes single-location practices as the dominant market model, but does not state the exact respondent count on the public page. The eight systems mapped here represent 929+ active clinics, so their shared-services, franchise, and multi-market problems should not be generalized to every med spa.
A lead is an intermediate event
The commercial outcome is an attended, profitable treatment and then repeat revenue, not the form fill. Consultation, no-show, treatment mix, financing, provider capacity, and membership renewal all sit between media and margin.
Three operating models create three different joins
A corporate network, a franchise system, and a premium multi-brand platform can all look like multi-location med spa from outside. They differ in who owns media, booking, pricing, capacity, and revenue data.
The offer system reduces risk before it sells treatment
Free consultation, personalized plan, financing or package economics, and membership or lifecycle care recur across the reviewed leaders. The offer is a sequence, not a single discount.
Public budget evidence is useful, but only at the right denominator
AmSpa's 2024 study supports a total-marketing benchmark and a wide observed range. Franchise disclosures support system-specific local-advertising obligations. Neither establishes a universal Google + Meta budget or category-wide CPL.
Health-data risk is specific to the entity, data, page, use, and destination
Google and Meta restrict sensitive-health targeting, while federal and state privacy duties depend on the actual data flow. 'Every med spa is HIPAA' and 'a public page is outside health privacy' are both unsafe shortcuts.
Three systems that should not share one benchmark
- 01
Corporate command center
Milan Laser · LaserAwayOne operator owns clinics, brand, offer system, and the majority of the acquisition path. The critical join is campaign → consultation → clinic → treatment → repeat revenue.
Market, clinic, provider capacity, treatment line - 02
Franchise growth system
VIO Med Spa · 4Ever YoungNational demand and brand rules meet franchisee-funded local media and local economics. Reporting has to distinguish required spend, discretionary spend, brand fund, and revenue by territory.
Franchisee, territory, fund, campaign, clinic P&L - 03
Premium platform
SkinSpirit · OVME · Ever/BodyA centralized brand and experience layer spans high-value services, memberships, and market-specific capacity. Treatment mix and lifecycle value matter more than a blended lead average.
Service line, membership, cohort, contribution margin
Category anchors: AmSpa industry statistics and 2024 State of the Industry recap . Location totals are dated lower bounds, not a live market census.
Creative evidence
The visual language is beauty retail; the outcome is clinical operations
Seasonal offers, beauty-category art direction, and quote-led conversion create demand. Performance still depends on attendance, provider capacity, treatment mix, financing, and repeat care at the selected clinic.
One seasonal frame combines treatment area, discount, and deadline
The acquisition mechanic is legible before a click: a bounded service bundle, a visible incentive, and a time-sensitive reason to act.
Beauty-category art direction makes treatment feel retail-native
The image borrows from fashion and beauty rather than clinical care, which explains why paid social and offer sequencing matter so much in this category.
The price journey begins with a custom quote
A quote-first entry protects flexible treatment economics, but it also creates a measurement handoff between media, consultation, financing, and care.
3 of 3 examples shown
Privacy boundary
One funnel can cross four different rule lanes
The correct question is not “Is med spa HIPAA?” It is which entity collected which data, on which surface, for what purpose, and where that data was sent.
Ad-platform targeting
Google restricts advertiser-curated audiences for sensitive health interests; Meta says it does not provide audience options around sensitive health topics.
Google and Meta policiesHIPAA-regulated flows
HHS guidance remains relevant where a regulated entity discloses protected health information. The 2024 court order narrowed one public-page interpretation; it did not erase the rest of the rule set.
HHS tracking guidanceNon-HIPAA consumer health data
The FTC Health Breach Notification Rule can apply to certain health apps and similar entities outside HIPAA.
FTC HBNRState consumer-health laws
Washington's My Health My Data Act creates a separate state-law lane for consumer health data and regulated entities.
Washington AGPrimary policy sources: Google Ads, Meta, HHS , FTC , and Washington State Attorney General . This map is not legal advice or a compliance finding.
Category shifts
Five shifts that rewired med spa marketing since 2025
- 01 tier a
The GLP-1 model survived the compounding shutdown; the claim set did not
The FDA ended enforcement discretion for compounded semaglutide as shortages resolved: April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities (tier a). Weight-management programs continue, but on brand-name terms with a narrower marketing claim set. The measurement consequence is structural: program revenue is recurring and cohort-shaped, and per-lead dashboards cannot see it.
FDA compounding statement - 02 tier c
Meta closed the lower funnel for health and wellness advertisers
Since January 2025, categorized health and wellness advertisers can lose the ability to optimize to purchase and booking-style events (Meta policy change, January 2025; Within explainer, tier c). For med spas that lands directly on the booked-consultation event. Accounts that own their outcome data keep optimizing; accounts that relied on pixel-side events lose their signal.
Meta guidance · Within analysis - 03 tier c
Tracking enforcement moved from theory to nine figures
Healthcare tracking penalties passed $100M across 19 public cases in 2023-2025 (Feroot analysis, tier c), California's Healthline action reached $1.55M under CCPA in July 2025 (tier c write-up of a public action), and Washington's My Health My Data Act adds a private right of action over consumer health data outside HIPAA (state AG overview, tier a). The tracking setup is now a bigger liability than the media plan for cash-pay health brands.
Feroot · Hintze Law · Washington AG - 04 tier c
Membership economics are the retention story, and the evidence is directional
Vendor-published figures put member lifetime value at roughly 3.5x non-members ($5,166 vs $1,495, Prospyr, methodology undisclosed, tier c) and general retention guidance at 50-70% (OptiMantra, tier c). None of this is audited, and this page treats it accordingly. The defensible version of the story comes from a client's own cohort data, which is exactly what a maturity stage 4 account can produce.
Prospyr · OptiMantra - 05 tier c
Consolidation is real, thin, and survivable evidence exists on both outcomes
Milan Laser reports 400+ clinics and LaserAway 226 (company announcements, tier c); VIO reports 64 locations with 200+ territories entering 2026 (company release, tier c). Ideal Image, formerly the category's third-largest footprint, collapsed with a 255-employee WARN filing and a $3.5M proposed Meta-pixel settlement, with allegations denied and no admission of liability (public filings, tier a). AmSpa's M&A retrospective puts EBITDA multiples at 3-6x under $4M revenue, 5-8x at $4-20M, and 7-12x above $20M (tier b): consolidation rewards the systems whose numbers survive diligence. In June 2026 Reuters reported that Ares was weighing a sale of LaserAway at more than $2bn (trade reporting of a wire story, tier c). Whatever comes of it, an operator at that size approaching a sale is exactly where the measurement debt comes due: diligence asks what a booked, attended, profitable treatment costs by location and channel, and that answer has to come from the operator's own joined data.
Company releases · WARN filing · AmSpa M&A retrospective 2026-05-15 · Reuters via Private Equity Wire 2026-06-05
Ideal Image is a transition case, not an active 150-location system
The category's third-largest chain came apart in pieces rather than in one sale: a 255-employee corporate closure in Florida, and selected clinics now listed in another operator's directory. What the public record supports is a transition, not a surviving system.
-
Ideal Image corporate retrenchment becomes visible
A Florida WARN filing records a Tampa corporate-office closure affecting 255 employees. It is an employment filing, not a complete clinic census.
-
Selected locations move to SEV
SEV's current location directory identifies several clinics as former Ideal Image locations. The evidence supports selected transitions, not a one-step acquisition of the whole system.
-
Avelure launches across 12 locations
Advanced MedAesthetic Partners launched Avelure across 12 locations and named the predecessor outright: the release says that in the wake of Ideal Image's restructuring in late 2025, patients were left searching for continuity in care.
-
Ideal Image is removed from the active cohort
The former 150-location estimate is not carried forward: the public domain no longer resolves, so the brand is a transition case rather than an active-system denominator.
Transition sources: Florida WARN filing , SEV directory, and Avelure announcement .
Footprints
Largest known operator footprints
Dated location counts from first-party public directories. They explain operating scale, not quality or performance.
Stage plays
Twelve plays, three per stage, each carrying its evidence basis
The plays assume the maturity model above: run the stage the account is actually in, and treat each basis line as the citation a client can check.
Platform defaults
- 01 Stand up consent management before adding any new tracking, on every client domain.
Healthcare tracking fines and settlements passed $100M across 2023-2025 (Feroot analysis of 19 public cases, tier c), and California's Healthline action ($1.55M, July 2025, tier c write-up of a public enforcement action) targeted ad tracking of health-related browsing specifically.
- 02 Move campaign optimization off lower-funnel events that Meta restricts for health and wellness advertisers; optimize to consultation-request or qualified-visit events instead.
Meta's restrictions took effect January 2025 and can remove purchase and booking-style optimization events for categorized advertisers (Meta policy change, January 2025; Within explainer, tier c).
- 03 Ask the client's biller one question: do we transmit electronic covered transactions? Record the answer in the account runbook.
HIPAA covered-entity status turns on electronic covered transactions, not on whether a treatment is medical (HIPAA Journal, 2026-06-18, tier c).
Owned tracking baseline
- 01 Record booked consultations as first-party conversion events on the client's own analytics property, not only inside ad platforms.
A lead is an intermediate event in this category's seven-step journey; platform-side counting stops before attendance and treatment (the seven-step journey inside the maturity model section).
- 02 Adopt one campaign and location naming convention across every channel ({brand}_{loc###}_{platform}_{funnel}_{offer}; booking events book_consult and consult_attended), so per-location reporting is a query rather than a project.
Per-location queries are only as good as the keys they group by, and franchise systems additionally need spend labeled by who owes it: FDD filings separate local obligations from brand funds (VIO's March 2026 filing requires 6% of gross sales on local marketing through month 24, then 4%, 2.5% and 1.5% as the location clears its minimum sales requirements, $3M and $4M in annual gross sales, tier a; 4Ever Young $7.5K/month plus 2%, third-party FDD review, tier c). In a franchise system the obligation moves with each location's revenue, so the report has to know which rung a location is on.
- 03 Import offline outcomes into the ad platforms weekly, under guardrails: documented consent basis, hashed identifiers only, generic event names (book_consult, consult_attended, never treatment terms), and keep Meta optimization on consultation-request because categorized health advertisers can have lower-funnel events stripped.
No defensible public med-spa CPL or CAC benchmark exists (benchmark reality section), so the account's own attended-consultation cost is the only benchmark that survives client scrutiny; the guardrails are what keep that measurement from becoming the exact data flow the enforcement wave prices (Meta restrictions tier c; penalty analysis tier c).
Location-grade attribution
- 01 Give every location its own tracked phone number with campaign attribution, including on Maps profiles, and configure the consent platform to load the call-tracking script post-consent with number insertion validated per location.
Milan Laser showed no call tracking at all while running ~9,000 active Google ads, ~8,000 of them Maps placements (capture 2026-07-26, tier a): Maps-heavy demand without call attribution is unmeasured demand. A consent platform that blocks the call-tracking script silently kills this attribution.
- 02 Reconcile booking-system outcomes to media weekly per location, and report no-show loss explicitly. Pass click identifiers into booking fields where the booking system allows; where it does not, use phone-match plus a stated time-window fallback.
Attendance is the first operational outcome in the journey; skipping it hides the step where media value actually leaks (the seven-step journey inside the maturity model section). The join key is the project: name it before promising the report.
- 03 Build the cost-per-attended-consultation metric per location per channel and make it the primary optimization number.
Platform lower-funnel lockouts (Meta, January 2025, tier c) make client-owned outcome joins the only reliable optimization signal for this category.
Warehouse-owned measurement
- 01 Schedule location-level marketing and booking exports into a client-controlled warehouse and document the consent and PHI boundary in writing.
Tracking enforcement (over $100M in penalties 2023-2025, tier c analysis of public actions) prices undocumented data flows; a written boundary is the cheapest control an agency can ship.
- 02 Cohort recurring revenue (memberships, weight-management programs) by acquisition campaign and location.
The FDA ended compounded-semaglutide enforcement discretion in 2025 (503A April 22, 503B May 22; tier a), pushing programs toward brand-name recurring models whose value per-lead dashboards cannot see.
- 03 Publish an internal per-location benchmark pack quarterly from warehouse data, tiered like this page's source register.
With no defensible public category benchmark (benchmark reality section), the agency's own warehouse-derived benchmarks become a sellable asset in reviews and pitches.
Agency scorecard
Six questions that decide whether an account is agency ready
Most med spas cannot support a tier-2 agency retainer, and pretending otherwise burns both sides. Six questions qualify an account before the pitch deck exists. Where a threshold cannot be derived from public evidence, it is stated as a decision question, not a number.
The agency-ready scorecard
| Qualifying question | Evidence anchor | What the answer decides |
|---|---|---|
| Is the account multi-location, or credibly on a multi-location path? | AmSpa reports 81% of the market is single-location (tier b). | The consolidated cohort's shared-services and per-location measurement problems are what justify tier-2 retainers; the median single-site practice does not have them. |
| Does 7% of the client's actual revenue fund your minimum engagement? | Total marketing averages 7% of revenue across a 2-15% range (Growth99's CEO on AmSpa's blog, 2025-05-02, citing AmSpa's 2024 report, tier c). Arithmetic, not a benchmark: at the $1,398,833 average revenue AmSpa's own recap reports, 7% is about $98K a year, or roughly $8,160 a month for all marketing combined, media included. | Run the multiplication on real revenue, then divide again: only part of total marketing is fee-able. State your fee floor against that share (decision question; no public benchmark exists). |
| Is the account above or below the $2,500/month marketing line? | A January 2026 AmSpa/Growth99 article (tier c) puts 52% of practices below $2,500 a month. Hold that against the $8,160 a month the row above implies at average revenue: the average and the median practice are not describing the same population, and the average is the one being quoted at you. | Below the line, productized reporting is the honest offer; above it, custom measurement can pay for itself. Ask which of the two numbers the account actually resembles before quoting either. |
| Does recurring revenue exist, or can it be built within two quarters? | The FDA's 2025 compounding wind-down (tier a) pushed weight-management programs toward brand-name recurring models; vendor-published membership economics are directional only (member LTV 3.5x non-member per Prospyr, methodology undisclosed, tier c). | Recurring revenue stabilizes retainer economics and requires cohort measurement, which is agency work. |
| If it is a franchise system: who owns the local advertising obligation and its data? | VIO's March 2026 FDD sets a 6% local-marketing requirement through month 24, then 4%, 2.5% and 1.5% as the location clears its minimum sales requirements, $3M and $4M in annual gross sales (tier a); 4Ever Young discloses $7.5K/month local plus a 2% brand contribution (third-party FDD review, tier c). | The FDD names your actual reporting counterparty: franchisee, brand fund, or both. It also indexes the obligation to each location's revenue, so a system-level average hides who actually owes what. |
| Can the account reach maturity stage 2 within one quarter? | Decision question against this edition's maturity model; no public threshold exists. | If consent and owned tracking are off the table, the account cannot be benchmarked or defended later. Price the foundations build as its own billable project, or pass. |
Implications
Optimize to treated, profitable revenue, not the cheapest lead
Carry campaign identity to treatment
Join source, offer, consultation, attendance, service line, discount, and collected revenue.
Put capacity beside acquisition
Read CAC with bookable slots, provider hours, no-shows, treatment mix, and contribution margin by clinic.
Govern measurement and activation separately
A permitted reporting flow does not automatically create a permitted audience or remarketing flow.
Pull quotes
Eight claims worth quoting, each carrying its tier
There is no defensible public med-spa CPL benchmark. The two nearest proxies inside a 3,542-campaign healthcare set, plastic surgery and dermatology, sit 5.5x apart at $102.51 and $18.54.
On one July day the two largest med-spa systems pulled in opposite directions: ~9,000 active Google ads and ~190 Meta at one; ~320 active Meta ads at the other, whose Google page showed a signed-out viewer just 14 ads, an age-gated floor.
AmSpa's 2024 survey puts 81% of med spas at a single location. The consolidated head of the category is the exception, not the average.
7% of revenue is the quoted average total marketing budget, and the range runs 2-15%. The number reaches you through a vendor, and nothing in public evidence splits it into Google plus Meta.
In med spa, you cannot borrow benchmarks, platform signal, or claims. Own the join, or pay the measurement debt at exit.
The FDA ended compounded-semaglutide discretion in 2025: April 22 for 503A pharmacies, May 22 for 503B facilities. The recurring-revenue model survived; the borrowed claim set did not.
Since January 2025, Meta can block health and wellness advertisers from optimizing to booking events. The event your dashboard optimized to may simply be gone.
A med spa's HIPAA status turns on electronic billing transactions, not on how medical a treatment feels. 'Every med spa is HIPAA' and 'none are' both fail.